offline
NeoGenomics
| 01.08.2019, 16:31 (Dieser Beitrag wurde zuletzt bearbeitet: 01.08.2019, 16:32 von Ste Fan.)
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO - Free Report) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post earnings of $0.05 per share when it actually produced earnings of $0.07, delivering a surprise of 40%.
Over the last four quarters, the company has surpassed consensus EPS estimates three time
.........................
http://www.zacks.com/stock/news/453508/n...-estimates?
![[Bild: NEOc1dl1028.png]](https://finviz.com/publish/080119/NEOc1dl1028.png)
NeoGenomics (NEO - Free Report) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post earnings of $0.05 per share when it actually produced earnings of $0.07, delivering a surprise of 40%.
Over the last four quarters, the company has surpassed consensus EPS estimates three time
.........................
http://www.zacks.com/stock/news/453508/n...-estimates?
